leadf
logo-loader
LSE:CIZ

Cizzle Biotechnology Holdings PLC

Receive alerts
Market:
LSE
Market Cap:
£12.52 m
Price
4.94 GBX
Change
0.82%
52 weeks high
13.00
52 weeks low
4.50

In brief

Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer.  

The company is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. 

Cizzle Biotechnology's proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B.  C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.